In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monogram Launches Companion Diagnostic To Pfizer’s New HIV Drug

This article was originally published in The Gray Sheet

Executive Summary

South San Francisco-based Monogram Biosciences launched its Trofile HIV diagnostic Aug. 6, timed with FDA approval of Pfizer's first-in-class HIV drug Selzentry (maraviroc) the same day

You may also be interested in...



LabCorp Buys Monogram Biosciences To Bolster Companion Dx Portfolio

LabCorp will expand its foothold in personalized medicine through its $155 million acquisition of companion diagnostics developer Monogram Biosciences

LabCorp Buys Monogram Biosciences To Bolster Companion Dx Portfolio

LabCorp will expand its foothold in personalized medicine through its $155 million acquisition of companion diagnostics developer Monogram Biosciences

Will Monogram's HER2 Test Hit The Mark?

On the same day that FDA approved Invitrogen's SPOT-Light test, South San Francisco-based Monogram Biosciences announced plans to make its own HER2 assay available to physicians as a lab service July 15. Monogram's data has not been reviewed by FDA, but the firm says its HERmark breast cancer assay may be more accurate than tests on the market. HERmark results have been correlated to immunohistochemistry and to fluorescence and chromogenic in situ hybridization results from more than 1,000 patients, showing "a high degree of concordance," according to Michael Bates, VP-clinical research. Monogram also says HERmark identifies patients with high HER2 levels who were identified as HER2-negative in other assays and those with low HER2 levels who were deemed positive. The assay uses specialized antibody tags to quantify the levels of HER2 protein, including protein that has bound together to create a new molecule, to generate a report that indicates a positive, negative, or equivocal HER2 status. HERmark is not an FDA-approved kit, but will be performed exclusively out of Monogram's laboratory, which is validated by the federal government to develop "home brew" diagnostic tests ("The Gray Sheet" Aug. 13, 2007, p. 5).

Related Content

UsernamePublicRestriction

Register

MT025133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel